Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences published its Q4 and full-year FY26 audited consolidated results on 16 May 2026. Consolidated total income for FY26 stood at Rs 3,422.83 million, up 8.7% from Rs 3,150.26 million in FY25. Net profit after tax surged 45.3% to Rs 574.84 million from Rs 395.71 million, with EPS of Rs 67.57 versus Rs 33.89 year-on-year. Q4 standalone income was Rs 978.92 million with standalone net profit after tax of Rs 263.84 million and EPS of Rs 31.01. The jump in annual profit outpaced revenue growth, indicating improved operational efficiency.
Strong double-digit profit growth with EPS nearly doubling makes this a positive signal for shareholders, suggesting the company improved profitability margins significantly in FY26.